NCT06045000View on ClinicalTrials.gov

Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 14, 2023

Primary Completion Date

October 2, 2023

Study Completion Date

October 2, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

DC-806

Oral tablets

DRUG

[14C]-DC-806

Oral capsules

Trial Locations (1)

9728 NZ

ICON Phase 1 Clinic, Groningen

All Listed Sponsors
lead

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

INDUSTRY